Once again Eisai screws up in Oncology. They make a sales guy (Tory) Director of Liver Mktg for Lenvima and he doesn’t know his ass from his elbow. Roche kicked our butts with their liver data with Atezo Bev so Lenvima is finished for liver. RCC is done. - noOncology pipeline here. I wonder how BS will spin this to us. DMs have left this year, reps will start en mass soon too Get out while you can
Eisai is such an embarrassment, at least in oncology. So big Pharma in our thinking and culture. Can’t wait to get out.
This is PHs legacy. He has never built up anything. he rides things into the ground and ensures he is compensated and rewarded. nothing shocking in this outcome.
Ha! This dates back even further to DTrex, MO’B, CS, LM, KW and of course the biggest dummy of them all LC. You could not find a less qualified, less knowledgeable, and less experienced in oncology than that ragtag of hacks. The Eisai oncology ship sunk before leaving the dock...
7 Merck reps, 3 Eisai reps=10 reps from ONE company calling on accounts trying to get an appointment. How many other companies are doing the same thing? BMS, Novartis, Lilly, J&J, Bayer, Sanofi, Pfizer, and others. Do you think our product is a priority? Keytruda, yes. We are going to end up making people mad.
